Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dual-target CAR-T Cells”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Very early researchNot Yet RecruitingNCT06986434
What this trial is testing

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Who this might be right for
Relapsed or Refractory Plasma Cell NeoplasmsLymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences 20
Not applicableLooking for participantsNCT06904131
What this trial is testing

A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors

Who this might be right for
Gynecological Solid Tumors
Obstetrics & Gynecology Hospital of Fudan University 20
Testing effectiveness (Phase 2)Looking for participantsNCT06235229
What this trial is testing

GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd. 110
Very early researchLooking for participantsNCT07350837
What this trial is testing

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

Who this might be right for
Highly Sensitized Patients Awaiting Kidney Transplant
Tongji Hospital 12
Testing effectiveness (Phase 2)UnknownNCT04723914
What this trial is testing

Dual Target CAR-T Cells in B-cell Lymphoma

Who this might be right for
Lymphoma, B-CellRelapse/RecurrenceRefractory Lymphoma+1 more
YuLi 20
Testing effectiveness (Phase 2)UnknownNCT06503094
What this trial is testing

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Testing effectiveness (Phase 2)UnknownNCT04723901
What this trial is testing

Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Dual-target CAR-T CellsB ALLRelapse+1 more
Shenzhen University General Hospital 20
Early research (Phase 1)Looking for participantsNCT07444307
What this trial is testing

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Early research (Phase 1)Looking for participantsNCT06153251
What this trial is testing

Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Early research (Phase 1)Looking for participantsNCT07003568
What this trial is testing

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Very early researchLooking for participantsNCT07249073
What this trial is testing

CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 9
Early research (Phase 1)Looking for participantsNCT07003555
What this trial is testing

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Early research (Phase 1)WithdrawnNCT04877080
What this trial is testing

CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL

Who this might be right for
B-cell Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Early research (Phase 1)Looking for participantsNCT06285279
What this trial is testing

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Who this might be right for
Lupus NephritisANCA-associated VasculitisMembranous Nephropathy - PLA2R Induced+1 more
Nanjing University School of Medicine 24
Early research (Phase 1)UnknownNCT05325801
What this trial is testing

CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Zhejiang University 9
Testing effectiveness (Phase 2)UnknownNCT03767751
What this trial is testing

A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Chinese PLA General Hospital 80
Early research (Phase 1)UnknownNCT05412329
What this trial is testing

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 9
Next Page